Abbott Laboratories (ABT) Tops Q2 EPS by 5c; Guides Above
More News related to ABT
- Absolute Software Acquires LANrev product suite from Pole Position Software
- Abbott and the Abbott Fund Honored With Corporate Citizenship Award for International Community Service
- Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
- Goldman Sachs Removed Abbott Labs (ABT) From Buy List, Eli Lilly (LLY) From Sell List
- Abbot Labs (ABT) To Transfer TriCor Rights to Teva Pharma (TEVA) as Soon as 2011
More News related to Earnings
- Highlights From SWHC Q2 Conference Call: First Qtr Reflected Results From Two Segments Under S&W Umbrella; Guides Below for Q3
- NASB Financial (NASB) Posts Q4 EPS of $0.77, Tops Views
- Highlights From Take-Two Interactive Softwares' (TTWO) Forecast Teleconference
- Saks (SKS) Restates Q3 EPS to $0.04, Up from $0.01
- Big Lots (BIG) Delivers With Strong Q3 Results and Guidance
Abbott Laboratories (NYSE: ABT) reports Q2 EPS of $0.84, versus the consensus of $0.79. Revenues came in at $7.31 billion, versus the consensus of $7.23 billion.
Sees Q3 EPS of $0.76-$0.78, versus the consensus of $0.79.
Sees FY EPS of $3.24-$3.28, versus the consensus of $3.23.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
-0.46Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
